Atlas Trials

Safety, Pharmacokinetics and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab in Participants With Solid Tumors in Chinese Participants

Clinical trial NCT05644626 · WITHDRAWN

Trial details

NCT number
NCT05644626
Sponsor
BeiGene
Status
WITHDRAWN
Phase
Phase 1
Study type
INTERVENTIONAL
Solid Tumors
Start date
2024-03-01
Primary completion
2025-03-01
Enrollment
0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.